The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent dilution.
Use a concentration of 0.2 - 1 µg/ml. Detects a band of approximately 20-28 kDa (predicted molecular weight: 23 kDa).
Use a concentration of 5 - 10 µg/ml.
FunctionMay be involved in macrophage-mediated cellular proliferation. It is mitogenic for fibroblasts and smooth muscle but not endothelial cells. It is able to bind EGF receptors with higher affinity than EGF itself and is a far more potent mitogen for smooth muscle cells than EGF. Also acts as a diphtheria toxin receptor.
Sequence similaritiesContains 1 EGF-like domain.
Post-translational modificationsSeveral N-termini have been identified by direct sequencing. The forms with N-termini 63, 73 and 74 have been tested and found to be biologically active. O-linked glycan attachment sites were determined by Edman degradation, O-glycanase digest suggests mucin-type glycosylation (done in HB-EGF purified from histiocytic lymphoma cell line U-937).
Cellular localizationCell membrane and Secreted > extracellular space. Mature HB-EGF is released into the extracellular space and probably binds to a receptor.
These images show Vero cells carrying
human HG-EGF expression vector (left hand image) and Vero cells carrying mouse HB-EGF expression vector (right hand image). Cells treated with ab 66792, fixed with 4% PFA and reacted with Cys3 conjugated 2nd antibody.
References for Anti-HB EGF antibody [4G10] (ab66792)
This product has been referenced in:
Tang XH et al. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer. Biochem Biophys Res Commun422:676-80 (2012).
Read more (PubMed: 22609777) »